How to validate a bioprocess digital twin for an intended decision

First define what the twin is allowed to inform

A twin cannot be evaluated in the abstract. State the decision, predicted endpoint, horizon, process and modality, operating range, user and consequence of an incorrect result. A model suitable for exploring development scenarios may need different evidence and controls from one used to monitor a manufacturing batch.

Keep model evaluation separate from computerized-system validation and from process validation. A good prediction score alone does not establish that a manufacturing process is validated or that a deployed system meets a regulated intended use.

1. Freeze a traceable evaluation dataset

• Record source systems, run identifiers, units, time alignment, exclusions and transformation versions.
• Check whether repeated samples, closely related runs or later observations could leak information into training.
• Preserve process phases, materials, equipment and assay methods so the model does not learn an accidental shortcut.
• Have a scientist review missing values and outliers before a result is scored.

2. Test on runs the model did not learn from

Set aside representative runs before fitting or tuning. Group related samples and campaigns when needed so the holdout is genuinely independent. Report error in the units and time horizon that matter for the decision, not just a single aggregate score.

If scale-up or technology transfer is the intended use, test the relevant scale, site, equipment or process version. A model that works only inside the training range should say so plainly.

3. Examine uncertainty and failure behavior

• Compare predicted intervals with observed outcomes and show where uncertainty grows.
• Probe missing sensors, late lab results, calibration shifts and unusual operating conditions.
• Identify out-of-domain cases and define whether the twin abstains, warns or routes to a reviewer.
• Inspect scientific constraints such as mass balance or known operating limits in a hybrid model.

4. Review the full workflow

Reproduce one output from original records through mapping, model inputs, model version, prediction and proposed action. Record who reviewed the result and what evidence they saw. If an AI assistant is involved, retain the tool actions and calculations behind its answer.

Change control matters after deployment: new source mappings, assays, equipment, data distributions or model versions can invalidate an earlier evaluation. Define monitoring, retraining triggers and re-evaluation before use expands.

A concise acceptance record

• Intended use and prohibited uses are written and approved.
• Held-out results meet a prespecified error and uncertainty criterion for each relevant operating range.
• Known failure cases are documented with a safe response.
• A reviewer can trace output to the selected run, source data and model version.
• The deployment has owners for monitoring, change control and periodic review.

Common questions

Sources and scope

These references inform the terminology and evaluation approach. They do not certify any software or replace a process-specific validation plan.

• FDA Process Validation: General Principles and Practices
• FDA Q8, Q9 and Q10 points to consider: model validation and verification
• ICH Q8(R2) pharmaceutical development